课题基金 / 基金详情

PHASE III TRIAL OF CRISNATOL MESYLATE VS BCNU IN BRAIN TUMOR PATIENTS

PHASE III TRIAL OF CRISNATOL MESYLATE VS BCNU IN BRAIN TUMOR PATIENTS
甲磺酸克瑞那醇 VS BCNU 在脑肿瘤患者中的 III 期试验
批准号：
6244935
负责人：
STEVEN K GUDEMAN
金额：
$1.34万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244935
关键词：
antineoplastics carmustine clinical research drug screening /evaluation glioblastoma multiforme human mortality human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer relapse /recurrence neoplastic process

项目摘要

项目成果

STEVEN K GUDEMAN的其他基金

相似基金

相关文献

中文摘要
翻译
主要目的是确定甲磺酸Crisnatol是否有效
英文摘要
The primary objective is to determine whether Crisnatol Mesylate is superior to BCNU as measured by time to tumor recurrence or progression in patients with glioblastoma multiforme. A secondary objective is to determine whether Crisnatol is superior to BCNU as measured by overall survival in patients with glioblastoma multiforme.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY
海外基金